Eurofins Viracor BioPharma Services — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Eurofins Viracor BioPharma is a specialized clinical research CRO offering end-to-end bioanalytical services from method development through regulated sample analysis for complex clinical programs. With a foundation dating back to 1988 and over 40 years of collective expertise, the company provides a validated test menu of over 3,000 assays and custom development capabilities, emphasizing scientific partnership, operational agility, and regulatory compliance (GCLP/GLP/GCP). Its integration into Eurofins Scientific provides scale and stability, positioning it as a trusted partner for biopharma innovators in translational research and precision medicine.

Infectious DiseaseOncologyImmunologyAllergy/Hypersensitivity

Technology Platform

Multi-platform bioanalytical services including Next-Generation Sequencing (NGS), digital PCR (dPCR), qPCR, RT-qPCR, flow cytometry, ligand-binding assays (ELISA, MSD), and cell-based assays for method development, validation, and sample testing.

Opportunities

Growing demand for specialized CRO services due to increasing complexity of drug modalities (cell/gene therapy, mRNA) and the rise of precision medicine creates a significant market opportunity.

The company's deep expertise in molecular and genomic testing, combined with the scale and stability of the Eurofins network, positions it to capture a larger share of outsourced bioanalytical work from biopharma sponsors.

Risk Factors

Key risks include the challenge of maintaining technological leadership amid rapid innovation, ensuring seamless integration within the large Eurofins organization, and the inherent cyclicality and potential client concentration in biopharma R&D spending.

Regulatory compliance failures could severely damage reputation and client trust.

Competitive Landscape

EVB competes in the fragmented bioanalytical CRO space against large, full-service CROs (IQVIA, Labcorp, PPD) and niche specialty labs. Its differentiation lies in its deep heritage in complex, esoteric infectious disease and molecular testing, a broad portfolio of over 3,000 validated assays, and the ability to act as a specialized partner within the vast Eurofins infrastructure.

More companies in Diagnostics & Precision Medicine →More companies in United States →